FinTechFunding

Imugene: Receives key U.S. patent for cancer therapies

  • Imugene (IMU) shares are trading green today on news the healthcare stock was granted a core U.S. patent
  • The patent protects Imugene’s B-Cell immunotherapy portfolio, which includes a range of cancer vaccines
  • Specifically, the new patient protects the composition and use of the vaccines, which are licenced by Ohio State University
  • Imugene’s CEO and Managing Director, Leslie Chong, said winning the key U.S. patent is a significant step for the company
  • The patent is valid up until 2035
  • Today, Imugene shares are up 3.92 per cent to trade for 5.3 cents each
Previous article
Accelerate Resources: Completes drilling at Comet Gold
Next article
Reward Minerals: Granted approval for Potash Project
Steve Sam
Steve Sam
Steve Sam is a financial reporter, analyst, and commentator with a strong focus on banking technology, digital payments, and the future of financial services.

You May Also Like

FinTech

eToro Strengthens Crypto Portfolio with Zengo Acquisition

Deal expands eToro's offerings in the cryptocurrency sector.Highlights: eToro is acquiring crypto wallet Zengo to expand its services.The...
FinTech

Revolut Launches Platform to Streamline Overseas Talent Hiring

Revolut's new service aims to simplify global recruitment for businesses.Highlights: Revolut launches a platform for hiring overseas talent.The...
FinTech

Revolut Strengthens Business Recruitment Platform in New Markets

The fintech giant expands its offerings targeting recruitment needs globally.Highlights: Revolut enhances its platform for business recruitment.The expansion...
FinTech

UniCredit Selects Slate to Strengthen Retail Investment Services

The partnership aims to enhance digital investment options for customers.Highlights: UniCredit partners with Slate for enhanced retail investment...